DE69527708D1 - Synthetischer impfstoff zum schutz gegen infektionen mit dem menschlichen immunschwächevirus - Google Patents

Synthetischer impfstoff zum schutz gegen infektionen mit dem menschlichen immunschwächevirus

Info

Publication number
DE69527708D1
DE69527708D1 DE69527708T DE69527708T DE69527708D1 DE 69527708 D1 DE69527708 D1 DE 69527708D1 DE 69527708 T DE69527708 T DE 69527708T DE 69527708 T DE69527708 T DE 69527708T DE 69527708 D1 DE69527708 D1 DE 69527708D1
Authority
DE
Germany
Prior art keywords
protect against
human immune
against infection
synthetic vaccine
immune virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69527708T
Other languages
English (en)
Other versions
DE69527708T2 (de
Inventor
Barton F Haynes
Thomas J Palker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Durham
Duke University
Original Assignee
University of Durham
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Durham, Duke University filed Critical University of Durham
Application granted granted Critical
Publication of DE69527708D1 publication Critical patent/DE69527708D1/de
Publication of DE69527708T2 publication Critical patent/DE69527708T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DE69527708T 1994-04-29 1995-04-28 Synthetischer impfstoff zum schutz gegen infektionen mit dem menschlichen immunschwächevirus Expired - Fee Related DE69527708T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23530594A 1994-04-29 1994-04-29
PCT/US1995/005465 WO1995029700A1 (en) 1994-04-29 1995-04-28 Synthetic vaccine for protection against human immunodeficiency virus infection

Publications (2)

Publication Number Publication Date
DE69527708D1 true DE69527708D1 (de) 2002-09-12
DE69527708T2 DE69527708T2 (de) 2003-04-30

Family

ID=22884945

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69527708T Expired - Fee Related DE69527708T2 (de) 1994-04-29 1995-04-28 Synthetischer impfstoff zum schutz gegen infektionen mit dem menschlichen immunschwächevirus

Country Status (10)

Country Link
EP (1) EP0762895B1 (de)
JP (1) JPH09512561A (de)
AT (1) ATE221786T1 (de)
AU (1) AU707894B2 (de)
CA (1) CA2189045A1 (de)
DE (1) DE69527708T2 (de)
DK (1) DK0762895T3 (de)
ES (1) ES2177648T3 (de)
PT (1) PT762895E (de)
WO (1) WO1995029700A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11515006A (ja) * 1995-10-20 1999-12-21 デューク・ユニバーシティー ヒト免疫不全ウイルス感染の予防用合成ワクチン
CA2358385C (en) 1998-12-31 2013-08-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
ID30407A (id) 1999-05-13 2001-11-29 American Cyanamid Co Formulasi-formulasi kombinasi bahan penambah
US6982086B2 (en) 2000-02-04 2006-01-03 Duke University Human immunodeficiency virus immunogenic composition
US7033593B2 (en) 2000-09-22 2006-04-25 Duke University Immunogen comprising an HIV envelope protein, a ligand and H2 peptide
JP2004511444A (ja) 2000-09-22 2004-04-15 デューク・ユニバーシティー 免疫原
EP1411770A4 (de) 2001-07-05 2006-05-10 Chiron Corp Polynukleotide, die für antigene hiv-polypeptide des c-typs codieren, polypeptide und ihre verwendung
US7195768B2 (en) 2001-11-07 2007-03-27 Duke University Polyvalent immunogen
AU2002363436A1 (en) 2001-11-07 2003-05-19 Duke University Polyvalent immunogen of hiv
US7172761B2 (en) 2001-11-07 2007-02-06 Duke University Polyvalent immunogen

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013548A (en) * 1987-09-08 1991-05-07 Duke University Production of antibodies to HIV
US5019387A (en) * 1987-09-08 1991-05-28 Duke University Production of antibodies to HIV

Also Published As

Publication number Publication date
WO1995029700A1 (en) 1995-11-09
CA2189045A1 (en) 1995-11-09
DK0762895T3 (da) 2002-09-02
DE69527708T2 (de) 2003-04-30
JPH09512561A (ja) 1997-12-16
EP0762895A1 (de) 1997-03-19
PT762895E (pt) 2002-11-29
ATE221786T1 (de) 2002-08-15
AU2372695A (en) 1995-11-29
EP0762895A4 (de) 1997-08-27
AU707894B2 (en) 1999-07-22
EP0762895B1 (de) 2002-08-07
ES2177648T3 (es) 2002-12-16

Similar Documents

Publication Publication Date Title
EE9900343A (et) Sünteetiline polünukleotiid, immuunvastuste tekitamise meetod, immunogeenne kompositsioon, anti-HIV immuunvastuste indutseerimise meetod, meetod antigeeni tekitava raku indutseerimiseks ja farmatseutiline kompositsioon
WO1993015205A3 (en) Synthetic haemophilus influenzae conjugate vaccine
DE69327587T2 (de) Konjugate von schwach immunogenen antigenen und synthetischen peptidträgern und impfstoffe diese enthaltend
MY103182A (en) Vaccines against acquired immune deficiency syndrome.
DE69527708D1 (de) Synthetischer impfstoff zum schutz gegen infektionen mit dem menschlichen immunschwächevirus
ATE359084T1 (de) Modifizierter hitzeschockprotein/peptidantigen komplex
GB8912651D0 (en) Peptide fragments of hiv
ATE302016T1 (de) Peptide, verwendet als träger in immunogenen konstrukten, die in der entwicklung synthetischer impfstoffe geeignet sind
KR920004422A (ko) Hiv의 주요 중화 결정인자
RU94040393A (ru) Синтетические пептиды для вакцины против краснухи
KR920002629A (ko) B형 간염 코어 항원의 아미노산 잔기 서열
EP0289110A3 (de) Konjugierter Malaria-Impfstoff
KR910011897A (ko) 말라리아 백신
CY1105176T1 (el) Χιμαιρικα νουκλεϊνικα οξεα και πολυπεπτιδια του ιου της λυσσας
DE69433057D1 (de) Peptide zur verwendung bei der impfung und induktion neutralisierender antikörper gegen das menschliche immunschwäche-virus
WO1989000861A1 (en) Vaccination against rabies-related viruses
ATE305941T1 (de) Impfstoff
AU2136488A (en) Vaccination against rabies-related viruses
RU97107302A (ru) Способ иммунизации против инфекции, вызываемой вирусом клещевого энцефалита
CO4750675A1 (es) Vacuna de env-glucoproteina para la proteccion contra la infeccion con vlcth-i y vclth-ii
RU95121713A (ru) Способ одновременной профилактики менингококковой инфекции, дифтерии, брюшного тифа, натуральной оспы, гриппа и вирусного гепатита
ES2065254A1 (es) Peptidos y vacunas sinteticas contra parvovirus canino y otros virus relacionados.
FR2698271B1 (fr) Vaccin contre le virus de la leucémie bovine, nouveau peptide immunogène et kit de vaccination.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee